VEGF-binding KDR polypeptide
US6348333B1 · kind B1 · utility
33Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 4, 1999 |
| Grant date | Feb 19, 2002 |
| Priority date | — |
| Expiry date | Mar 4, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel polypeptide is provided, which can be utilized to treat diseases accompanying neovascularization, such as solid tumors, and is useful as a low molecular weight VEGF inhibitor. The polypeptide contains immunoglobulin-like domain 1 and immunoglobulin-like domain 2 of the extracellular domain of the VEGF receptor KDR. Since it has smaller molecular weight than the conventional polypeptides with retaining VEGF inhibitory activity, it is expected that it can be readily expressed using recombinant DNA techniques and infiltrates into diseased sites more quickly.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.